Prior to joining Mountainfield, Adam most recently worked in business development at HilleVax, supporting both buy-side and sell-side partnering activities. This included leading cross-functional diligence and negotiating an exclusive license for Chengdu Kanghua’s hexavalent norovirus vaccine candidate.
Earlier in his career, Adam was a consultant at ClearView Healthcare Partners, advising clients ranging from emerging biotechs to large pharmaceutical companies. His work spanned corporate strategy, commercial opportunity assessments, and indication prioritization across a wide range of therapeutic areas.
Adam also serves as Senior Director, Business Development at Timberlyne Therapeutics, a Mountainfield-founded company.
Adam received his MBA from Harvard Business School and holds a BS from Cornell University.